Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
VRTX - Vertex Pharmaceuticals Incorpor
Market Cap 92.31B P/E 28.51 EPS this Y -97.80% Ern Qtrly Grth -
Income -489.9M Forward P/E 22.18 EPS next Y 5,443.70% 50D Avg Chg 4.00%
Sales 10.34B PEG 119.06 EPS past 5Y 27.36% 200D Avg Chg 12.00%
Dividend N/A Price/Book 5.97 EPS next 5Y 12.33% 52W High Chg -2.00%
Recommedations 2.20 Quick Ratio 2.10 Shares Outstanding 258.10M 52W Low Chg 32.00%
Insider Own 0.08% ROA 12.96% Shares Float 257.33M Beta 0.41
Inst Own 95.59% ROE -3.24% Shares Shorted/Prior 4.34M/4.42M Price 358.40
Gross Margin 53.65% Profit Margin -4.74% Avg. Volume 1,274,488 Target Price 512.20
Oper. Margin 35.34% Earnings Date Nov 4 Volume 2,166,599 Change 3.07%
Healthcare | Biotechnology | United States
About Vertex Pharmaceuticals Incorpor

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorpor News
11/20/24 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 48% Below Their Intrinsic Value Estimate
11/19/24 Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
11/18/24 3 Growth Stocks You Can Buy Right Now Without Any Hesitation
11/13/24 Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
11/12/24 GILD or VRTX: Which Is the Better Value Stock Right Now?
11/09/24 Five S&P 500 Stocks On This Elite IBD List Near Buy Points
11/08/24 Stock Market: Three Top Names In Buy Zones, One With Earnings Due
11/08/24 2 Biotech Stocks You Can Buy Hand Over Fist This Month
11/08/24 Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
11/06/24 Vertex Pharmaceuticals (VRTX) Just Overtook the 20-Day Moving Average
11/06/24 Vertex Pharmaceuticals (VRTX) Crossed Above the 50-Day Moving Average: What That Means for Investors
11/06/24 Vertex Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
11/06/24 Moderna said to shuffle sales leadership; Vertex records first Casgevy sale
11/05/24 Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
11/05/24 Vertex Flashes A Surprise Buy Point As Non-Opioid Pain Drug Looms
11/05/24 Vertex shares up after full-year product revenue guidance boost
11/05/24 Top Midday Stories: Boeing Workers Approve Labor Contract, End Strike; Palantir Raises FY Revenue Guidance
11/05/24 VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
11/05/24 5 Top Stocks to Buy in November
11/05/24 Q3 2024 Vertex Pharmaceuticals Inc Earnings Call
VRTX Chatroom

User Image fritokalo Posted - 20 hours ago

$VRTX depending on how suz does I think this has a good shot at being a four digit stock in 2026.

User Image fritokalo Posted - 21 hours ago

$VRTX if data from LSR trial is good then this closes above $600 by EOY. Then if both drugs get approved in January I see $700-800 by end of Q1 25.

User Image Timefortendies77 Posted - 21 hours ago

$VRTX Under 450 is borderline ridiculous. I hope the Suz P2 comes through well.

User Image Poppy_McIntosh Posted - 21 hours ago

$VRTX $BMY LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image Aitana_Low Posted - 22 hours ago

$VRTX $C LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image fritokalo Posted - 23 hours ago

$VRTX according to this discounted cash flow analysis fair value is almost a double from this price. https://ca.finance.yahoo.com/news/vertex-pharmaceuticals-incorporated-nasdaq-vrtx-120016555.html

User Image Monkey_Banana_Genius Posted - 23 hours ago

$VRTX data from the LSR trial imminent and will have major impact on short term stock price. R/r gets better as stock price comes down into this readout. https://clinicaltrials.gov/study/NCT06176196?cond=Lumbosacral%20Radiculopathy&spons=Vertex%20Pharmaceuticals%20Incorporated&rank=1

User Image biotech Posted - 1 day ago

$VRTX "Entire pain franchise could exceed $10B" re $SGMO

User Image biotech Posted - 1 day ago

$SGMO This is great timing and another potential source of cash due to partnering NAV1.7 , ST-503 #PAIN $SGMO CEO in London speaking to pot. BP partners right now. we could see $VRTX interest as they show NAV1.7 as next wave in presentation also $PFE had interest in NAV1.7 in the past

User Image biotech Posted - 1 day ago

$SGMO WellsFargo sees $3B+ opportunity in #Neuropathic #pain $VRTX NAV1.8 / $SGMO NAV1.7 ST-503 Zinc Finger Repressor

User Image Timefortendies77 Posted - 1 day ago

$VRTX Wow I can't even remember the last time it went below 450. I took this as a buy opp. This will be an insanely successful Pharma with Suz on the market.

User Image SternInvesting10 Posted - 1 day ago

$VRTX big buying opportunity

User Image fritokalo Posted - 1 day ago

$VRTX probably needs to get back above the 200 day moving average by the end of the week or this could drop a lot more. Crazy to think that no buyers are stepping up with multiple catalysts over the next 70 days!

User Image swingingtech Posted - 1 day ago

$VRTX https://wallstreetwaves.com/significant-200-day-moving-average-crossover-in-vertex-pharmaceuticals-vrtx/

User Image fritokalo Posted - 1 day ago

$VRTX looks like no fomo...clock is running down...

User Image fritokalo Posted - 1 day ago

$VRTX the Stifel conference was today. Can anyone hear something bad in this? https://investors.vrtx.com/events/event-details/stifel-healthcare-conference

User Image fritokalo Posted - 1 day ago

$VRTX this is how they steal your shares. Nobody knows the results of the readout, if they did there would be lawsuits.

User Image Monkey_Banana_Genius Posted - 1 day ago

$VRTX data must be forthcoming, peeps scared and selling it off. 👀

User Image WhoKnocks Posted - 1 day ago

$VRTX I’m down 5% on this monkey. I figures for some churn but Jeesh. I’m in this for a year+ but it’s still crappy to see.

User Image hydel Posted - 1 day ago

$VRTX Idk seems somebody knows something

User Image JCLuckman Posted - 1 day ago

$VRTX Rare entry point for this Cash monopoly machine 🗣️🤓

User Image ElijahJobs Posted - 1 day ago

$VRTX Wait, just realized that this thing is now under the 200-day MA... hmm. Usually it bounces off of that.

User Image ElijahJobs Posted - 1 day ago

$VRTX The VRTX options makers are absolutely criminals and assholes. Not giving me low price calls even the stock is down by $16 today. WTF?

User Image Freydis Posted - 1 day ago

$VRTX i am a sucker @50 weekly

User Image fritokalo Posted - 1 day ago

$VRTX they are obviously trying to scare retail out of the stock so they can accumulate.

User Image Timefortendies77 Posted - 1 day ago

$VRTX That's it--it's adding time boys--we know when this dips to 450s it comes back to close or above 500 every time.

User Image fritokalo Posted - 1 day ago

$VRTX at this point I think it's safe to say that a bad readout for chronic pain is baked into the share price. So this is derisked, and with a good readout we fly!

User Image fritokalo Posted - 1 day ago

$VRTX for everyone thinking a bad readout for chronic pain has leaked I can pretty much guarantee it hasn't.

User Image saladressing Posted - 1 day ago

$VRTX hope I caught the bottom at 452.24 for a few more shares.

User Image fritokalo Posted - 1 day ago

$VRTX selling now would be like selling $NVDA in 2022.

Analyst Ratings
Morgan Stanley Equal-Weight Oct 1, 24
RBC Capital Sector Perform Sep 19, 24
HC Wainwright & Co. Buy Aug 5, 24
Oppenheimer Outperform Aug 5, 24
JP Morgan Overweight Aug 5, 24
Truist Securities Buy Aug 5, 24
Barclays Equal-Weight Aug 5, 24
Guggenheim Buy Aug 2, 24
Cantor Fitzgerald Overweight Aug 2, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bozic Carmen EVP and CMO EVP and CMO Oct 03 Sell 345.28 5,651 1,951,177 46,254 10/05/23
Ambrose Kristen SVP & Chief Accounti.. SVP & Chief Accounting Officer May 30 Sell 329.82 289 95,318 6,838 06/01/23
Tatsis Ourania EVP, Chief Reg. & Qu.. EVP, Chief Reg. & Quality Off. Feb 24 Sell 288.27 354 102,048 56,805 02/28/23
Arbuckle Stuart A EVP, COO EVP, COO Feb 24 Sell 287.89 5,034 1,449,238 56,556 02/28/23
Ambrose Kristen SVP & Chief Accounti.. SVP & Chief Accounting Officer Feb 24 Sell 288.52 1,207 348,244 7,303 02/28/23
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Feb 24 Sell 288.52 4,238 1,222,748 32,038 02/28/23
Arbuckle Stuart A EVP, COO EVP, COO Feb 22 Sell 294.14 2,401 706,230 66,304 02/24/23
Arbuckle Stuart A EVP, COO EVP, COO Feb 17 Sell 293.03 2,402 703,858 68,705 02/22/23
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Feb 17 Sell 293.13 4,002 1,173,106 40,246 02/22/23
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Feb 06 Sell 304.48 1,304 397,042 68,645 02/08/23
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Feb 06 Option 187.53 1,304 244,539 69,949 02/08/23
Kewalramani Reshma CEO & President CEO & President Jan 25 Sell 315.05 10,000 3,150,500 89,598 01/27/23
Lee Yuchun Director Director Jan 17 Sell 312.1 4,442 1,386,348 1,875 01/19/23
Lee Yuchun Director Director Jan 17 Option 72.14 4,442 320,446 2,317 01/19/23
Sanna Bastiano EVP, Cell & Genetic.. EVP, Cell & Genetic Therapies Oct 18 Sell 300.93 1,791 538,966 39,192 10/20/22
Kewalramani Reshma CEO & President CEO & President Aug 15 Sell 305.06 11,689 3,565,846 99,598 08/17/22
Arbuckle Stuart A EVP, COO EVP, COO Aug 15 Option 155.57 6,571 1,022,250 67,451 08/17/22
Arbuckle Stuart A EVP, COO EVP, COO Aug 15 Sell 303.05 22,173 6,719,528 45,278 08/17/22
Liu Joy SVP, General Counsel SVP, General Counsel Aug 15 Sell 303.14 3,747 1,135,866 9,605 08/17/22
Bhatia Sangeeta N. Director Director Aug 08 Sell 292.97 621 181,934 4,661 08/10/22
Liu Joy SVP, General Counsel SVP, General Counsel Aug 09 Sell 300.00 946 283,800 13,388 08/10/22
Tatsis Ourania EVP, Chief Reg. & Qu.. EVP, Chief Reg. & Quality Off. Aug 09 Sell 299.68 1,400 419,552 46,090 08/10/22
Arbuckle Stuart A EVP, COO EVP, COO Aug 09 Option 155.57 1,926 299,628 66,686 08/10/22
Arbuckle Stuart A EVP, COO EVP, COO Aug 09 Sell 300.98 5,690 1,712,576 60,996 08/10/22
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Aug 08 Sell 292.8 1,304 381,811 36,077 08/10/22
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Aug 08 Option 187.53 1,304 244,539 37,381 08/10/22
Bhatia Sangeeta N. Director Director Jul 29 Sell 279.58 621 173,619 5,282 08/02/22
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Jul 19 Option 171.55 17,765 3,047,586 53,942 07/21/22
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Jul 19 Sell 288.18 17,865 5,148,336 36,077 07/21/22
Arbuckle Stuart A EVP, COO EVP, COO May 02 Sell 263.98 306 80,778 64,760 05/04/22
Sanna Bastiano EVP, Cell & Genetic.. EVP, Cell & Genetic Therapies May 02 Sell 259.66 320 83,091 41,696 05/04/22
Bhatia Sangeeta N. Director Director May 02 Sell 259.81 737 191,480 5,903 05/04/22
WAGNER CHARLES F JR EVP & Chief Financia.. EVP & Chief Financial Officer May 02 Sell 259.61 343 89,046 42,730 05/04/22
Lee Yuchun Director Director Apr 18 Option 81.54 2,000 163,080 3,875 04/20/22
Lee Yuchun Director Director Apr 18 Sell 284.68 2,000 569,360 1,875 04/20/22
Lee Yuchun Director Director Apr 14 Option 81.54 2,000 163,080 3,875 04/18/22
Lee Yuchun Director Director Apr 14 Sell 289.45 2,000 578,900 1,875 04/18/22
LEIDEN JEFFREY M Executive Chairman Executive Chairman Apr 13 Sell 289.04 15,789 4,563,653 74,160 04/14/22
Lee Yuchun Director Director Apr 12 Option 81.54 4,000 326,160 3,875 04/14/22
Lee Yuchun Director Director Apr 12 Sell 284.86 4,000 1,139,440 1,875 04/14/22
Lee Yuchun Director Director Apr 08 Option 81.54 4,000 326,160 3,875 04/12/22
Lee Yuchun Director Director Apr 08 Sell 279.38 4,000 1,117,520 1,875 04/12/22
Bhatia Sangeeta N. Director Director Apr 08 Option 125.71 1,907 239,729 7,098 04/12/22
Bhatia Sangeeta N. Director Director Apr 08 Sell 280.2 1,907 534,341 5,191 04/12/22
MCGLYNN MARGARET G Director Director Apr 08 Option 127.54 5,000 637,700 6,099 04/12/22
MCGLYNN MARGARET G Director Director Apr 08 Sell 280.84 5,000 1,404,200 1,099 04/12/22
Lee Yuchun Director Director Apr 06 Option 81.54 4,000 326,160 3,875 04/08/22
Lee Yuchun Director Director Apr 06 Sell 273.12 4,000 1,092,480 1,875 04/08/22
Sanna Bastiano EVP, Cell & Genetic.. EVP, Cell & Genetic Therapies Apr 07 Sell 276.37 561 155,044 42,782 04/08/22
Sanna Bastiano EVP, Cell & Genetic.. EVP, Cell & Genetic Therapies Apr 04 Sell 270.25 3,725 1,006,681 43,343 04/06/22